Arcus Biosciences Inc (NYSE:RCUS) was up 6.4% during trading on Wednesday following insider buying activity. The company traded as high as $8.53 and last traded at $8.29. Approximately 239,500 shares were traded during mid-day trading, an increase of 103% from the average daily volume of 118,082 shares. The stock had previously closed at $7.79.
Specifically, CEO Terry J. Rosen purchased 41,540 shares of the stock in a transaction that occurred on Tuesday, June 4th. The shares were acquired at an average price of $7.91 per share, for a total transaction of $328,581.40. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Terry J. Rosen purchased 21,738 shares of the stock in a transaction that occurred on Thursday, June 6th. The stock was purchased at an average price of $7.93 per share, for a total transaction of $172,382.34. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 105,343 shares of company stock valued at $842,228. Company insiders own 19.23% of the company’s stock.
A number of equities research analysts recently weighed in on RCUS shares. Citigroup restated a “buy” rating and issued a $25.00 price target on shares of Arcus Biosciences in a report on Friday, May 24th. BTIG Research started coverage on Arcus Biosciences in a report on Monday, March 18th. They issued a “buy” rating and a $20.00 price target on the stock. Svb Leerink restated an “outperform” rating on shares of Arcus Biosciences in a report on Friday, May 3rd. Finally, Zacks Investment Research upgraded Arcus Biosciences from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a report on Thursday, March 7th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Arcus Biosciences currently has a consensus rating of “Buy” and an average target price of $17.50.
Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.07). The firm had revenue of $1.75 million during the quarter, compared to analyst estimates of $1.25 million. Arcus Biosciences had a negative return on equity of 22.72% and a negative net margin of 613.46%. As a group, analysts forecast that Arcus Biosciences Inc will post -1.64 earnings per share for the current year.
A number of large investors have recently made changes to their positions in the business. BVF Inc. IL grew its holdings in Arcus Biosciences by 16.5% during the 1st quarter. BVF Inc. IL now owns 2,810,223 shares of the company’s stock valued at $35,100,000 after buying an additional 398,600 shares during the last quarter. Geode Capital Management LLC grew its holdings in Arcus Biosciences by 12.0% during the 1st quarter. Geode Capital Management LLC now owns 202,995 shares of the company’s stock valued at $2,535,000 after buying an additional 21,823 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Arcus Biosciences by 5.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 98,736 shares of the company’s stock valued at $1,234,000 after buying an additional 4,897 shares during the last quarter. Trexquant Investment LP acquired a new stake in shares of Arcus Biosciences during the first quarter worth $204,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Arcus Biosciences during the first quarter worth $149,000. Hedge funds and other institutional investors own 46.58% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Arcus Biosciences (NYSE:RCUS) Trading Up 6.4% After Insider Buying Activity” was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.chaffeybreeze.com/2019/06/12/arcus-biosciences-nysercus-trading-up-6-4-after-insider-buying-activity.html.
Arcus Biosciences Company Profile (NYSE:RCUS)
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial.
Further Reading: Certificate of Deposit (CD)
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.